Drug Profile
PR8 mRNA
Alternative Names: PR8 mRNA-LNPLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Acuitas Therapeutics
- Class Influenza virus vaccines; RNA vaccines
- Mechanism of Action Gene transference; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus infections
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Influenza-A-virus-infections(Prevention) in Canada (Intradermal)
- 28 May 2021 No recent reports of development identified for preclinical development in Influenza-A-virus-infections(Prevention) in USA (Intradermal)
- 22 Feb 2018 Arbutus terminates Acuitas right to use or sublicense LNP technology